Stifel Nicolaus Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $2.00

Health Catalyst (NASDAQ:HCAT) had its price objective lowered by analysts at Stifel Nicolaus from $3.75 to $2.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 51.52% from the stock’s current price.

Other analysts have also issued reports about the stock. Cantor Fitzgerald cut their target price on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Friday. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday. Citigroup dropped their price target on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Raymond James Financial set a $3.00 price objective on shares of Health Catalyst in a research report on Friday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst has a consensus rating of “Hold” and an average target price of $3.16.

Health Catalyst Trading Down 26.3%

Shares of NASDAQ:HCAT opened at $1.32 on Friday. The stock has a market capitalization of $93.36 million, a price-to-earnings ratio of -0.52 and a beta of 1.76. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. The stock’s 50-day simple moving average is $2.05 and its two-hundred day simple moving average is $2.56. Health Catalyst has a 52-week low of $1.20 and a 52-week high of $5.06.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 3.98%. The business had revenue of $74.68 million for the quarter, compared to analysts’ expectations of $73.99 million. Analysts expect that Health Catalyst will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after acquiring an additional 2,624 shares during the period. Campbell & CO Investment Adviser LLC boosted its position in shares of Health Catalyst by 9.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock worth $162,000 after purchasing an additional 3,808 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Health Catalyst by 19.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after purchasing an additional 4,341 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Health Catalyst by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after purchasing an additional 6,832 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Health Catalyst by 6.5% during the 4th quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock valued at $283,000 after purchasing an additional 7,186 shares during the period. Institutional investors own 85.00% of the company’s stock.

Key Health Catalyst News

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.